Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
Annals of the New York Academy of Sciences|November 5, 1997
Clinical trials in dementia with propentofyllineB Kittner, M Rössner, M RotherAnnals of the New York Academy of Sciences|January 17, 1996
HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer typeM Rother, B Kittner, K Rudolphi, et al.Dementia and Geriatric Cognitive Disorders|September 23, 1997
A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study GroupJ Marcusson, M Rother, B Kittner, et al.Dementia and Geriatric Cognitive Disorders|August 26, 1998
Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trialsM Rother, T Erkinjuntti, M Roessner, et al.Alzheimer Disease and Associated Disorders|October 13, 1998
Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trialsR Mielke, H J Möller, T Erkinjuntti, et al.Alzheimer Disease and Associated Disorders|December 28, 1999
Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study GroupB KittnerEuropean Journal of Pharmacology|August 7, 1986
Apomorphine does not decrease tissue levels of tetrahydrobiopterin in vivoM Bräutigam, B Kittner, H HerkenNaunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1986
Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivativesG Laschinski, B Kittner, M BräutigamMolecular Pharmacology|December 1, 1985
Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomesM Bräutigam, B Kittner, G LaschinskiJournal of Medicine|January 1, 1987
On the assessment of the efficacy of pentoxifylline (Trental)M Rössner, R MüllerPageof 8